Home » Topics » Nephrology, BioWorld Science

Nephrology, BioWorld Science
RSS

New Hsp70 inducers presented by scientists in the Netherlands

Nov. 11, 2013

Phase II trial of Zerenex in NDD-CKD meets all primary and key secondary endpoints

Nov. 7, 2013

Genkyotex begins multinational phase II study of NOX inhibitor

Nov. 5, 2013

Development of Kremezin discontinued in the U.S. and Europe

Oct. 31, 2013

Sophiris begins dosing in PLUS-1 phase III trial of PRX-302

Oct. 30, 2013

Enrollment complete in phase III trial of ZS-9 for treatment of hyperkalemia

Oct. 24, 2013

Evotec and AstraZeneca collaborate on treatments for chronic kidney disease

Oct. 22, 2013

Relypsa reports topline data from phase IIb trial of patiromer

Oct. 18, 2013

Phase I trial of KEA-0447/KRP-EPA605 for treatment of overactive bladder begins

Oct. 18, 2013

Relypsa announces topline data from second part of patiromer phase III trial

Oct. 11, 2013

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 13, 2026.
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
AAIC 2026: Age of amyloid is being joined by time of tau
BioWorld
The Alzheimer’s Association International Conference (AAIC) is the world’s biggest dementia conference. And at the AAIC 2026 meeting, there is big buzz around...
NRF2 activators reported in Vailima Peninsula patent
BioWorld Science
Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...